Eating Disorders
Customize your policy alerts
Sign up for Aetna Policy 0511 alerts
Get alerted when Policy 0511 changes without checking for updates manually.
Monitor payer policy activity
Defines Aetna's medical necessity, experimental/investigational determinations, covered assessments and treatments, and related coding for management of anorexia nervosa, bulimia nervosa and binge-eating disorder for insured members.
No material clinical or coverage changes in this revision.
Coverage Criteria
inv-01: Assessment (Medically necessary)
Medically necessary when ALL of the following assessment components are documented:
Documentation should include results and clinical interpretation; bone density testing targeted to anorexic patients as noted.
inv-02: Treatment (Medically necessary)
Covered treatments when clinically indicated and documented:
Pharmacotherapy subject to formulary restrictions and plan benefit exclusions for weight‑altering medications; enteral nutrition only as a last resort for anorexia.
inv-03: Experimental / Investigational (Not established)
The following services are considered experimental and investigational (not established) due to insufficient evidence:
Listed as experimental/investigational for diagnosis and treatment.
Listed as experimental/investigational for treatment.
inv-04: Coverage-considerations based on evidence
Evidence-based considerations and implied coverage positions:
From evidence reviews and guideline summaries.
AHRQ and subsequent reviews.
Multiple RCTs and systematic reviews summarized.
Small/single‑center RCTs or single‑group data; further controlled trials required.
Systematic reviews and guideline recommendations.
Coverage of pharmacologic treatment is subject to plan and formulary rules. The policy lists pharmacotherapy as a medically necessary treatment option for anorexia, bulimia and binge‑eating disorder but notes that coverage of particular drugs may be subject to formulary restrictions. In addition, the policy explicitly warns that coverage of lisdexamfetamine for binge‑eating disorder may be excluded under plans that exclude medications to decrease or increase weight; reviewers and billing staff should confirm member benefit documents before authorizing or submitting claims.
The policy identifies the Mandometer residential program and the ION™ (Individual Optimal Nutrition) analysis/profile as interventions with limited or unestablished clinical value. The Mandometer program’s published evidence is largely from a single Swedish group and non‑comparative series; Aetna notes that effectiveness has not been established and that a randomized trial versus standard care is needed. Similarly, the ION profile is described as a broad panel of biochemical and nutrient measures for which there is a lack of evidence supporting clinical value in diagnosing or evaluating eating disorders. These modalities may therefore be treated as investigational or excluded depending on plan rules.
The policy highlights a safety concern for application of excitatory non‑invasive brain stimulation (notably rTMS) in anorexia nervosa: narrative reviews report a trend toward iatrogenic weight loss with excitatory NIBS in AN and conclude that excitatory stimulation may be contraindicated on theoretical and empirical grounds. This caution should inform clinical decision‑making and payer review of requests for rTMS in members with anorexia.
The document summarizes background research across many diagnostic and treatment approaches without making standalone coverage determinations for each. For several novel or emerging interventions (for example, residential programs, device‑based neuromodulation, and e‑therapies), the available studies are small, single‑center, or uncontrolled and thus insufficient to establish long‑term effectiveness. The policy therefore compiles the evidence base and flags modalities as experimental/investigational where peer‑reviewed data do not meet standards for established medical benefit.
The USPSTF‑commissioned systematic review cited in the policy limited its analysis to adolescents and adults without underweight or overt physical signs of an eating disorder; accordingly, evidence that is limited to under‑weight populations or to patients with physical signs (e.g., rapid weight loss, pubertal delay, bradycardia, oligomenorrhea or amenorrhea) was excluded from that review. The policy notes the USPSTF conclusion that current evidence is insufficient to determine the balance of benefits and harms of screening in adolescents and adults without signs or symptoms.
The policy lists numerous diagnostic tests and therapeutic approaches that are considered experimental and investigational because of insufficient peer‑reviewed evidence. Examples include: brain imaging (MRI, PET, SPECT) for diagnosis/treatment planning; a range of genetic polymorphism tests (COMT, ESR1, 5‑HTTLPR, MC4R); blood‑based serotonergic biomarkers; EEG for management; gut microbiota evaluation; the ION nutritional profiling; measurement of multiple peripheral biomarkers (BDNF, adiponectin, hypothalamic neuropeptides, polyunsaturated fatty acids); and measurements of serum zinc. On the treatment side, listed investigational therapies include acupuncture, ghrelin agonists, GLP‑1 receptor agonists, intranasal naloxone, liraglutide, neural therapy, biofeedback/neurofeedback, music therapy, Mandometer treatment, repetitive TMS, deep brain stimulation for refractory anorexia, and many others. These items are identified in the policy’s Experimental and Investigational section and should be handled as not medically necessary absent compelling peer‑reviewed evidence and applicable plan language.
A small randomized, double‑blind, sham‑controlled trial of rTMS in bulimia nervosa (Walpoth et al., n=14) found no additional benefit of active stimulation over sham on bingeing and purging or commonly used mood and obsessive‑compulsive scales. The policy cites these negative randomized data when listing repetitive transcranial magnetic stimulation for BN among investigational or not‑medically‑necessary interventions.
Within the excerpted material there are numerous statements identifying investigational procedures and summarizing evidence, but the text does not always include explicit formal determinations phrased as 'not medically necessary' for every intervention. Instead, the policy groups many interventions into an Experimental and Investigational list and states that items in that list are considered investigational because evidence is insufficient; reviewers should reference the Experimental and Investigational section for specific determinations rather than expect a separate 'not medically necessary' statement for each item in this excerpt.
Coding
| 76977 | Ultrasound bone density measurement and interpretation, peripheral site(s), any method. |
| 77078 | Computerized tomography, bone mineral density study, 1 or more sites. |
| 77080 | Dual energy x-ray absorptiometry (DXA), bone density study, 1 or more sites. |
| 77081 | Dual energy x-ray absorptiometry (DXA), additional code (listed in range 77080 - 77081). |
| 80047 | Basic metabolic panel (Calcium, ionized). |
| 80048 | Basic metabolic panel (Calcium, total). |
| 80050 | General health panel. |
| 80053 | Comprehensive metabolic panel. |
| 80076 | Hepatic function panel. |
| 81000 | Urinalysis. |
| 70450 | Computed tomography, head or brain (listed in range 70450 - 70470). |
| 70496 | Computed tomographic angiography, head, with contrast material(s). |
| 70551 | Magnetic resonance imaging, brain (listed in range 70551 - 70553). |
| 70554 | Functional MRI, brain (listed in range 70554 - 70555). |
| 78600 | Brain imaging (nuclear medicine) (listed in range 78600 - 78610). |
| 81403 | Molecular pathology procedure level 4. |
| 84630 | Zinc (measurement). |
| 96900 | Actinotherapy (ultraviolet light). |
| 97812 | Acupuncture subsequent sessions (listed in range 97810 - 97814). |
| A4633 | Replacement bulb/lamp for ultraviolet light therapy system. |
| F50.00 | Anorexia nervosa. |
| F50.01 | Anorexia nervosa, other. |
| F50.02 | Anorexia nervosa, unspecified. |
| F50.2 | Bulimia nervosa. |
| F50.81 | Binge eating disorder. |
| F50.82 | Avoidant/restrictive food intake disorder. |
| R63.0 | Anorexia. |
| Z13.21 | Encounter for screening for nutritional disorder [eating disorders] (listed as not covered). |
| No codes listed |
Provider Actions & Administrative Notes
Advanced procedures / implant coding noted
Advanced procedures and implant-related codes (e.g., deep brain stimulation CPT codes) are listed as not covered for indications in this CPB — verify coding and medical necessity prior to submission to avoid denials.
Prior authorization for experimental/long-term programs
Prior authorization may be required for experimental, novel, or long-term residential/specialty programs (for example, unproven modalities like Mandometer residential programs). Submit clinical rationale, prior treatment history, objective measures of severity, and expected length of stay when requesting authorization.
- Document prior outpatient treatment attempts and clinical need for higher level of care
- Include program description and planned therapeutic components
- Provide expected treatment duration and measurable goals
Lisdexamfetamine (Vyvanse) for BED
Lisdexamfetamine (Vyvanse) is an FDA‑approved pharmacotherapy for binge‑eating disorder (BED). Coverage may be subject to formulary restrictions or plan exclusions for weight‑altering medications; prior authorization may apply per benefit plan.
- Check member's drug formulary and any PA or quantity limits
- If PA required, provide BED diagnosis, prior therapies tried, and treatment goal
Prior authorization not specified in excerpt
In the provided excerpts, no specific prior authorization requirements are explicitly stated for many services (e.g., enteral nutrition supplies, NG feeding). Treating providers should check the member's benefit plan and medical policy for any PA rules before providing services.
- Verify benefit plan prior authorization rules for enteral nutrition and related supplies
- Coding lists do not equate to PA approval — submit clinical documentation as needed
Prior authorization not specified in provided text
Some coding entries and background sections note that prior authorization is not specified in the provided text (e.g., enteral nutrition HCPCS groups). This is informational; operational PA rules may be maintained separately.
- Check administrative PA lists or pharmacy benefit for medication-specific requirements
- Do not assume no PA — confirm with payer portal or policy documents
Prior authorization not specified in this section
Within this section, no explicit prior authorization or utilization management rules are stated for several interventions (e.g., DBS, NG feeding, residential programs). Operational PA requirements should be confirmed with the payer.
- Confirm PA requirements for investigational/high-cost procedures (e.g., DBS) before referral
- When in doubt, submit pre-service review to avoid retrospective denials
Screening code not covered
Screening for eating disorders (ICD-10 Z13.21) is designated as not covered in this CPB because screening clinical value has not been established in the literature presented.
- Do not bill Z13.21 for covered diagnostic services under this CPB; use diagnostic codes when clinical disorder is identified
Investigational modalities risk denial
Investigational modalities (for example, Mandometer programs, certain residential treatments, DBS for AN) carry a risk of denial because clinical value and long-term effectiveness have not been established.
- Document rationale and evidence when requesting authorization for novel modalities
- Be prepared for denials when therapies are labeled investigational in policy
Lack of controlled trials showing long‑term effectiveness
There is a documented lack of controlled trials demonstrating long‑term effectiveness for some higher‑level care settings (notably residential treatment) and for several interventions, which may limit coverage justification for prolonged stays or novel programs.
- Provide objective outcome data and justification for continued length of stay when requesting ongoing coverage
- Consider step‑down to evidence‑based outpatient or PHP where appropriate
Not applicable in this excerpt — no explicit operational rules
Not applicable in this excerpt: no explicit step therapy or formal utilization management rules are detailed. Use the policy content as clinical guidance and consult administrative PA/UM documents for operational rules.
- Operational rules (PA, step therapy) may be maintained separately from this CPB
- Contact payer UM team for program‑specific authorization criteria
No explicit authorization or prior‑approval stated
The excerpt does not state explicit authorization or prior‑approval processes for many services; providers must verify PA requirements through the payer's administrative channels.
- Confirm PA for high‑cost medications, implants, and residential services before initiating treatment
- Include supporting clinical documentation with any PA request
Required assessment documentation
Required assessment documentation for medical necessity determinations should include medical history and physical exam details, psychiatric/psychological evaluation, relevant labs (CBC, electrolytes, BUN/creatinine, LFTs), EKG results, and bone density testing when indicated.
- Include baseline weight/percent expected body weight and recent weight trend
- Attach relevant lab results and EKG when requesting higher level of care or enteral nutrition
Bone health therapy documentation
When documenting bone‑health therapies (e.g., bisphosphonates, hormone replacement), include rationale, prior efforts at weight restoration, bone mineral density results, fracture history, and discussion of limited evidence and risks.
- Document failure of or contraindication to weight restoration when proposing bone‑targeted therapy
- Note informed consent discussing uncertain benefit and potential risks
When naso‑gastric feeding is used for AN
When naso‑gastric (NG) feeding is used for anorexia nervosa, document the indication (e.g., life‑threatening malnutrition or failure of oral refeeding), short‑term weight gain goals, monitoring plan (electrolytes, refeeding protocol), and adherence issues.
- Provide daily caloric targets and expected rate of weight gain
- Document monitoring for refeeding syndrome and prophylactic measures (eg, phosphate supplementation)
No explicit documentation or medical necessity template provided
No explicit documentation templates or medical necessity checklists are provided in the excerpts; use the assessment and treatment elements noted in the policy as the basis for documentation submitted for authorizations.
- Supply clinical notes, lab results, psychiatry/psychology evaluations, and prior treatment chronology when requesting authorization
Pharmacotherapy sequencing note
Pharmacotherapy sequencing: prioritize weight restoration and evidence‑based psychosocial therapies for anorexia nervosa before initiating pharmacologic treatments; for bulimia, use evidence‑based agents (e.g., fluoxetine) as first‑line when indicated.
- For AN: emphasize nutritional rehabilitation and psychotherapy before meds
- For BN: consider fluoxetine before other agents unless contraindicated
Step from evidence‑based therapy to experimental medications
When considering experimental or off‑label medications, step from established evidence‑based therapies to novel agents only after documented failure or intolerance of first‑line treatments; include risk/benefit discussion and safety monitoring plan.
- Document prior trials of psychotherapy and approved/standard pharmacotherapies
- Include monitoring plan for adverse effects and objective outcome measures
Medication selection considerations
Medication selection considerations: fluoxetine is the only FDA‑approved medication for bulimia nervosa; other agents (eg, topiramate, bupropion, lisdexamfetamine) have mixed evidence or specific safety concerns that should be documented when used.
- Avoid bupropion in bulimia due to seizure risk
- When using topiramate or stimulants, document informed consent and monitor for adverse events
No formal step‑therapy rules are specified
No formal step‑therapy rules are specified in the provided excerpts; the document summarizes trial evidence and clinical guidance but does not prescribe utilization management sequencing.
- Operational step therapy, if any, should be confirmed via administrative PA criteria
No step‑therapy rules are described in the text
Several study summaries describe pharmacotherapy trials and suggested sequences, but no operational step‑therapy rules are described in the text — these are clinical references, not UM directives.
- Use clinical trial evidence to support medical necessity but verify payer's step therapy lists separately
Background
Eating disorders include anorexia nervosa and bulimia nervosa and typically present in adolescence or young adulthood with a predominance in females. The policy notes estimated lifetime prevalence in adult women (e.g., AN 1.42%, BN 0.46%, BED 1.25%) and lower prevalence in men, and highlights the potential for severe medical complications. Most patients can be managed in outpatient settings; hospitalization is reserved for severe medical instability (for example, extreme low body weight, electrolyte disturbances, cardiac arrhythmias, or suicidality). Weight restoration and multidisciplinary care (medical monitoring, nutritional counseling and psychotherapy) are central to management.
Definitions
Level of Care Criteria
inv-68: Inpatient/Medical refeeding (enteral nutrition) — evidence summary
Evidence summary for enteral nutrition in anorexia nervosa:
Used as medical refeeding in inpatient settings and considered when oral refeeding insufficient or life‑threatening condition present.
Treatment Modalities
inv-70: Psychotherapy, Nutritional Counseling, Pharmacotherapy
Primary behavioral treatments; indicated across eating disorder presentations as clinically appropriate.
Nutrition emphasized as central intervention.
Subject to formulary restrictions and benefit exclusions for weight‑altering medications.
inv-71: rTMS
Excitatory NIBS may be contraindicated in anorexia due to a trend toward iatrogenic weight loss in some reports.
inv-72: Residential behavioral program (Mandometer)
Evidence primarily from single‑group reports and limited trials; not validated as standard care.
inv-73: Pharmacologic (BED)
Lisdexamfetamine trials demonstrated reductions in binge days; topiramate reduced binge frequency but had higher withdrawal for adverse effects.
inv-74: Non-invasive and invasive brain stimulation
DBS has small observational data in treatment‑refractory AN; rTMS/tDCS findings mixed and further trials needed.
inv-75: Bright light therapy
Systematic review identified small studies with short‑term benefit.
inv-76: Behavioral inhibition training
Pilot proof‑of‑concept data support further study.
inv-77: Pharmacologic treatments
Guideline and evidence review consensus.
inv-78: Ghrelin agonists (relamorelin)
Preliminary randomized data; not established therapy.
inv-79: GLP-1 receptor agonists
Research and pilot data support further trials.
inv-80: Phentermine/topiramate ER (Qsymia)
Preliminary RCT evidence; further study required for routine use in EDs.
inv-81: Enteral nutrition (nasogastric tube) for AN
Used in hospital settings for medical refeeding when oral intake insufficient or life‑threatening condition exists.
inv-82: Neural therapy (superficial injection)
Evidence limited to case reports; controlled studies needed.
inv-83: Oxytocin (intranasal)
Pilot and early‑phase data only.
inv-84: Enteral Nutrition (NG)
Enteral nutrition considered when clinically indicated; closely monitored in hospital settings.
inv-85: Pharmacotherapy (lisdexamfetamine, topiramate)
Evidence includes multiple RCTs and meta‑analyses summarized.
inv-86: Neurofeedback / EEG / Biofeedback
Systematic reviews report small number of heterogeneous studies; further research needed.
inv-87: Gut microbiota evaluation / interventions
Research findings are preliminary and methods heterogeneous.
inv-88: Pharmacologic, neuromodulation, psychosocial (music therapy)
Examples include liraglutide pilot trials, DBS for refractory AN (small observational studies), and music‑based interventions with limited generalizability.
inv-89: Various modalities (pharmacotherapy, psychotherapy, neuromodulation, nutritional support)
Refer to cited references for detailed trial data and systematic reviews.
Visit Limits
References & Revision History
References cited in the policy include guideline and systematic review sources and key randomized trials across pharmacologic, psychotherapy, neuromodulation and nutritional interventions. Representative citations include practice parameters and reviews (AACAP/APA sources), randomized trials and RCTs (e.g., lisdexamfetamine trials for BED), systematic reviews of neurostimulation and enteral nutrition, and topical studies on biomarkers and genetics. See the policy’s reference list for full citations and to guide further literature review.
Clinical policy bulletin last reviewed.
Policy effective date established.
Next scheduled policy review date.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.